Your email has been successfully added to our mailing list.

×
0 -0.00477326968973758 -0.00477326968973758 -0.00477326968973758 0.00238663484486868 0.00190930787589499 0.00238663484486868 0.00954653937947495
Stock impact report

Flex Pharma launches mid-stage study of FLX-787 in ALS [Seeking Alpha]

FLEX PHARMA (FLKS) 
Last flex pharma earnings: 8/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.flex-pharma.com/investor-overview
Company Research Source: Seeking Alpha
Flex Pharma ( FLKS ) initiates a Phase 2 clinical trial, COMMEND , assessing Fast Track-tagged FLX-787 for the treatment of patients with motor neuron disease (MND), primarily amyotrophic lateral sclerosis (AML), who are experiencing painful, debilitating cramps. The primary endpoint of the 120-subject study is cramp frequency over 28 days compared to placebo. Top-line data should be available in mid-2018. The company describes FLX-787 as a  transient receptor potential ion channel  activator, specifically a co-activator of the proteins TRPA1 and TRPV1. Previously: Flex Pharma's FLX-787 Fast Track'd in U.S. for ALS-related muscle cramps; shares ahead 9% premarket (July 25) Now read: Healthcare - Top 5 Gainers / Losers as of 11:00 am » Show less Read more
Impact Snapshot
Event Time:
FLKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for FLKS alerts
Opt-in for
FLKS alerts

from News Quantified
Opt-in for
FLKS alerts

from News Quantified